BurnsKereburnNCT03984331
Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns
A study testing Fish skin and Cadaver skin in people with Burns, run by Kerecis Ltd. at 1 site in United States.
Trial summary
Objectives and rationale: Optimal burn management involves removing all the dead or burned tissue as early as feasible and cover with an autograft called split thickness skin graft (STSG) taken from the patient. Read more about this study
- Who is it for?
- Ages 22 to 75 years
- Conditions the study is for
- Burns
- What is being tested?
- Fish skin and Cadaver skin
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteUnited States
- Study dates
- 14 Feb 2019to 21 Sep 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant or legally authorized representative is willing and able to give informed consent for participation in the clinical trial.
- Patients from 22 to 75 years of age. Acute full thickness burn wounds outside the following areas; facial, genital and across joints, requiring widely meshed skin grafting or staging of STSG treatment due to insufficient healthy donor sites.
- Maximal Total Body Surface Area (TBSA) of 50% full thickness burns
- Able (in the Investigators opinion) and willing to comply with all clinical trial requirements.
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the clinical trial.
Who cannot join
- Declined consent
- Immunocompromised patients or patients receiving immunosuppressive therapy
- Presently participating in another clinical trial
- Patient actively taking glucocorticoid or cytostatic medications
- Persons with immune deficiency because of disease or iatrogenic-
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the clinical trial, or may influence the result of the clinical trial, or the participant's ability to participate in the clinical trial.
- Patient has known allergy to fish. (Shell fish allergy is not a contraindication)
- Female participants who are pregnant, breast feeding or planning pregnancy during the course of the clinical trial
Trial locations and contacts
1 site in 1 country.
United States1 site
Burn Center at Medstar Washington Hospital Center
Washington D.C., District of Columbia, 20010
About this study
Official title: MariGen Fish Skin Compared to Cadaver Skin as a Temporary Covering for Full Thickness Burns: An Early Feasibility Trial
Objectives and rationale: Optimal burn management involves removing all the dead or burned tissue as early as feasible and cover with an autograft called split thickness skin graft (STSG) taken from the patient. This procedure creates a new wound on the patient and sometimes, when the burn covers very large portion of the patient body, there is a lack of healthy skin to use for this purpose. Under those circumstances, donated cadaver skin is used as a temporary coverage until the patient´s own donor site wound has healed enough to be used again.
The proposed clinical study aims to determine if treatment with fish skin is an alternative to cadaver skin as a temporary coverage for debrided full-thickness burns prior to STSG in terms of autograft take, time to heal, quality of healing (scarring), pain and adverse effects.
Read the detailed description
Mortality after severe burns has diminished during the last decades and survival is no longer considered the primary end point of care. More attention is paid to the final functional and cosmetic outcome of the affected area but outcomes are still far from optimal. For the time being, one of the main goals in burn treatment is to achieve reduced scar formation from the time of injury. A temporary or permanent covering of the wound bed should be achieved at the time of excision. In burn wounds the gold standard is to use split thickness skin graft, or STSG, which includes epidermis, basement membrane, and a part of upper dermis. Yet the use of skin grafts has many shortcomings: there is only a limited amount of skin available for grafting, the donor sites are susceptible to infections, to pain, to pigmentation changes, and to scarring especially when re harvested. Therefore, for complicated burns, initial treatment is often with temporary coverage where cadaver skin has been the accepted standard of care.
In recent years there has been progress in the development of advanced wound care products. This has resulted in a third generation of wound treatment, known as acellular dermal grafts or skin substitutes.
Aims The goal of this clinical trial is to demonstrate that fish skin is an alternative to cadaver skin as early cover before STSG in burn wounds. This trial will be open to patients who are scheduled to receive meshed STSG of any ratio. Fish skin or cadaver skin will be applied after initial debridement in order to prepare the wound area for STSG.
5 to 10 patients will be prospectively enrolled and two burn sites on their body will randomized to initial treatment after debridement with either fish skin or cadaver skin for 7+/-3 days. After the initial treatment, the test sites will be grafted with STSG.
The histological differences and the functional outcomes will be assessed for 12 months.
Products will be applied by experienced burn surgeons at a burn center. At approximately Day 7, or when the treating physician deems the wound to be ready for grafting, the products will be removed. Prior to grafting, a second blinded burn surgeon will assess the burn wound bed.
Important dates for blinding are on Day 7 prior to STSG treatment and on Days 14, 21 and 28 for graft take, epithelialisation and wound closure. Scar assessment at 3 and 12 months via the Vancouver Scar Sale will also be fully blinded.
Key interventions:
Randomized to either cadaver skin or fish skin after initial debridement Two areas each of 10-20 x 7 cm side by side. Other areas will be treated as per local Standard of care (SOC). Concomitant medications will be given, e.g. painkiller, antibiotics, as needed.
Wound dressings changed approximately every three days until allograft or xenograft removal.
Approximately one week after placement the fish skin and cadaver allografts removed as required.
Subsequent meshed autograft placement if donor sites are available. Autografts covered with secondary antimicrobial/silver dressing and dressings approximately every 3 days until healed.
Autografts monitored for adherence, color, autograft take, and visual signs of infection.
During the operation, a 3 or 4 mm punch biopsy will be harvested from the excised wound bed before covering with any material.
- Conditions
- Burns
- Being tested
- Fish skin, Cadaver skin
- Keywords
- Fish skin, Full thickness burn, Burns, Cadaver Skin, Split Thickness Skin Graft, Temporary Cover, Blaze, Kerecis
- Medical subject headings
- Burns, Ichthyosis Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fish skinDevice
Also called Marigen TM, Kerecis Omega3 Burn
One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
Cadaver skinDevice
One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
| Study group | Role | What they receive |
|---|---|---|
| Fish skin | Experimental | All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin. Receives: Device: Fish skin |
| Cadaver skin | Active comparator | All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin. Receives: Device: Cadaver skin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportions of wounds that have healed
Wounds which have reached at least 95% epithelialization
Measured: At 3 weeks days after STSG
Secondary outcomes (11)
Percentage of wound area exhibiting graft failure
The proportion of the wound area in which the graft does not take
Measured: At 2 weeks after STSG
Full epithelialization of wound
Number of wounds fully epithelialized
Measured: At 2 weeks after STSG
Scarring estimated with the Vancouver Scar Scale (VSS)
Vascularity (0-3), pigmentation (0-3), pliability (0-3), height (0-3), Total score;0=Best, 12=worst
Measured: At 12 months after STSG
Inflammation profiling of wound punch biopsies as assessed by histology
Histological analysis of punch wound biopsies via standard H\&E staining, or staining for known inflammatory markers (TNF-alpha, IL-1b, IL-6, IL-8)
Measured: Before STSG, 2 and 3 weeks and 12 months after STSG
Average number of antibiotics treatments per patient
Average number of antibiotics treatments per patient
Measured: At all treatments appointments until 4 weeks after STSG
Pain assessed by the Visual Analog Scale (VAS) before and after dressing changes
Pain by the Visual Analog Scale (VAS) on a scale of 0-10, 0=no pain, 10= pain as bad as it could be
Measured: At all treatments appointments until 3 weeks after STSG
Bleeding time
Average time in seconds to achieve hemostasis during dressing changes
Measured: At all treatments appointments until 3 weeks after STSG
Dermatitis
Incidence of dermatitis
Measured: At all treatments appointments until 3 weeks after STSG
Ease-of-use
Ease-of-use as judged by attending physician on a VAS scale of 0=extremely difficult to use to 10=Very easy to use
Measured: Day 0 when grafts are initially applied after debridement
Incidence of hematoma
Nr of wounds which develop a hematoma
Measured: At all treatments appointments until 3 weeks after STSG
Inflammatory profiling of wound punch biopsies as assessed by mass spectrometry
Mass spectrometry analysis of punch wound biopsies, investigating known inflammatory markers (TNF-alpha, IL-1b, IL-6, IL-8)
Measured: Before STSG, 2 and 3 weeks and 12 months after STSG
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2019
- Study start14 Feb 2019
- Primary completion8 Jun 2021
- Study completion21 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BurnsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two adjacent burn sites on the body of each burn patient will be randomized to receive initial early cover treatment after debridement with either fish skin or cadaver skin for 7± 3 days. After the initial 7± 3 days the test sites will be grafted with STSG.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kerecis Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- MedStar Health
- Responsible party
- Sponsor
- Investigators
- Jeffrey W. Shupp, MD, Principal investigator, Medstar Health Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03984331
- Sponsor's protocol ID
- KS-0340 - P2587
- Other IDs
- CDMRP-MB150220
- Acronym
- Kereburn
- Status last verified
- Jul 2022
- First submitted
- 10 Jan 2019
- Last updated
- 6 Jul 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MariGen Fish Skin Compared to Cadaver Skin as a Temporary Covering for Full Thickness Burns: An Early Feasibility Trial
- ClinicalTrials.gov ID
- NCT03984331
- Acronym / sponsor ID
- Kereburn / KS-0340 - P2587
- Conditions
- Burns
- Keywords
- Fish skin, Full thickness burn, Burns, Cadaver Skin, Split Thickness Skin Graft, Temporary Cover, Blaze, Kerecis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Kerecis Ltd.Industry (pharma, biotech, devices)
- Collaborators
- MedStar Health
- Study start
- 14 Feb 2019 (actual)
- Primary completion
- 8 Jun 2021 (actual)
- Study completion
- 21 Sep 2021 (actual)
- First posted
- 13 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objectives and rationale: Optimal burn management involves removing all the dead or burned tissue as early as feasible and cover with an autograft called split thickness skin graft (STSG) taken from the patient. This procedure creates a new wound on the patient and sometimes, when the burn covers very large portion of the patient body, there is a lack of healthy skin to use for this purpose. Under those circumstances, donated cadaver skin is used as a temporary coverage until the patient´s own donor site wound has healed enough to be used again.
The proposed clinical study aims to determine if treatment with fish skin is an alternative to cadaver skin as a temporary coverage for debrided full-thickness burns prior to STSG in terms of autograft take, time to heal, quality of healing (scarring), pain and adverse effects.
Detailed description
Mortality after severe burns has diminished during the last decades and survival is no longer considered the primary end point of care. More attention is paid to the final functional and cosmetic outcome of the affected area but outcomes are still far from optimal. For the time being, one of the main goals in burn treatment is to achieve reduced scar formation from the time of injury. A temporary or permanent covering of the wound bed should be achieved at the time of excision. In burn wounds the gold standard is to use split thickness skin graft, or STSG, which includes epidermis, basement membrane, and a part of upper dermis. Yet the use of skin grafts has many shortcomings: there is only a limited amount of skin available for grafting, the donor sites are susceptible to infections, to pain, to pigmentation changes, and to scarring especially when re harvested. Therefore, for complicated burns, initial treatment is often with temporary coverage where cadaver skin has been the accepted standard of care.
In recent years there has been progress in the development of advanced wound care products. This has resulted in a third generation of wound treatment, known as acellular dermal grafts or skin substitutes.
Aims The goal of this clinical trial is to demonstrate that fish skin is an alternative to cadaver skin as early cover before STSG in burn wounds. This trial will be open to patients who are scheduled to receive meshed STSG of any ratio. Fish skin or cadaver skin will be applied after initial debridement in order to prepare the wound area for STSG.
5 to 10 patients will be prospectively enrolled and two burn sites on their body will randomized to initial treatment after debridement with either fish skin or cadaver skin for 7+/-3 days. After the initial treatment, the test sites will be grafted with STSG.
The histological differences and the functional outcomes will be assessed for 12 months.
Products will be applied by experienced burn surgeons at a burn center. At approximately Day 7, or when the treating physician deems the wound to be ready for grafting, the products will be removed. Prior to grafting, a second blinded burn surgeon will assess the burn wound bed.
Important dates for blinding are on Day 7 prior to STSG treatment and on Days 14, 21 and 28 for graft take, epithelialisation and wound closure. Scar assessment at 3 and 12 months via the Vancouver Scar Sale will also be fully blinded.
Key interventions:
Randomized to either cadaver skin or fish skin after initial debridement Two areas each of 10-20 x 7 cm side by side. Other areas will be treated as per local Standard of care (SOC). Concomitant medications will be given, e.g. painkiller, antibiotics, as needed.
Wound dressings changed approximately every three days until allograft or xenograft removal.
Approximately one week after placement the fish skin and cadaver allografts removed as required.
Subsequent meshed autograft placement if donor sites are available. Autografts covered with secondary antimicrobial/silver dressing and dressings approximately every 3 days until healed.
Autografts monitored for adherence, color, autograft take, and visual signs of infection.
During the operation, a 3 or 4 mm punch biopsy will be harvested from the excised wound bed before covering with any material.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Two adjacent burn sites on the body of each burn patient will be randomized to receive initial early cover treatment after debridement with either fish skin or cadaver skin for 7± 3 days. After the initial 7± 3 days the test sites will be grafted with STSG.
| Arm | Type | Receives |
|---|---|---|
| Fish skin | Experimental | Device: Fish skinAll patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin. |
| Cadaver skin | Active comparator | Device: Cadaver skinAll patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin. |
Who may qualify
- Ages
- 22 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Participant or legally authorized representative is willing and able to give informed consent for participation in the clinical trial.
Key exclusion criteria (8 listed)
- Declined consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fish skinAlso: Marigen TM, Kerecis Omega3 BurnOne out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft. | Device | Fish skin |
| Cadaver skinOne out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft. | Device | Cadaver skin |
Primary outcome
Proportions of wounds that have healed
Time frame: At 3 weeks days after STSG
Wounds which have reached at least 95% epithelialization
11 secondary outcomes
Percentage of wound area exhibiting graft failure
Time frame: At 2 weeks after STSG
Full epithelialization of wound
Time frame: At 2 weeks after STSG
Scarring estimated with the Vancouver Scar Scale (VSS)
Time frame: At 12 months after STSG
Inflammation profiling of wound punch biopsies as assessed by histology
Time frame: Before STSG, 2 and 3 weeks and 12 months after STSG
Average number of antibiotics treatments per patient
Time frame: At all treatments appointments until 4 weeks after STSG
Pain assessed by the Visual Analog Scale (VAS) before and after dressing changes
Time frame: At all treatments appointments until 3 weeks after STSG
Bleeding time
Time frame: At all treatments appointments until 3 weeks after STSG
Dermatitis
Time frame: At all treatments appointments until 3 weeks after STSG
Ease-of-use
Time frame: Day 0 when grafts are initially applied after debridement
Incidence of hematoma
Time frame: At all treatments appointments until 3 weeks after STSG
Inflammatory profiling of wound punch biopsies as assessed by mass spectrometry
Time frame: Before STSG, 2 and 3 weeks and 12 months after STSG
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Burns
RecruitingObservational study
Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn Patients
Sepsis, Sepsis-induced Coagulopathy
Not yet recruitingObservational study
Hypertrophic Scar Prosthetic Pressure in Burn Amputee
Amputation Stump, Burn Injury
Not yet recruiting
Effect of Short-Video Distraction During Burn Dressing on Anxiety, Pain, and Fear in Children
Burn Injury, Procedural Anxiety
RecruitingObservational study
Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn Patients
Peer Bullying Intervention, Vodcast
RecruitingPhase 2
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Pruritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jeffrey W. Shupp, MD principal investigator
Medstar Health Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fish skin and Cadaver skin in people with Burns, run by Kerecis Ltd. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportions of wounds that have healed (time frame: At 3 weeks days after STSG). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2022.